BridgeBio Pharma, Inc. (BBIO)
BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.
Address
3160 PORTER DR.
PALO ALTO, CA 94304
Founded
2015
Number of Employees
550
Website
http://www.bridgebio.com
Buyback
| Buyback Data | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $ Amount Purchased ($ in 000s ) |
- | - | - | - | - | - | - | $200,014 | - | - | - | $200,014 |
| Average Price | - | - | - | - | - | - | - | $52.95 | - | - | - | $52.95 |
| # Shares Purchased | - | - | - | - | - | - | - | 3,777,080 | - | - | - | 3,777,080 |
| Buyback Performance | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Return to Date | - | - | - | - | - | - | - | -50.9% | - | - | - | -50.9% |
| S&P 500 Return to Date | - | - | - | - | - | - | - | 31.7% | - | - | - | 31.7% |
| Excess Total Return | - | - | - | - | - | - | - | -82.6% | - | - | - | -82.6% |
| Quartile Rank |
|
|
|
|
|
|
|
|
|
|
|
|
| Percentile Rank | - | - | - | - | - | - | - | 14% | - | - | - | 14% |
Buyback returns calculated using weighted average buyback price over the last 10 years and comparing to current day stock price value. S&P 500 used as benchmark for excess return.
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)
Never miss an email alert when insiders at BBIO make a trade.
Creating a free account takes less than one minute